Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis.
<h4>Background</h4>A nonavalent human papillomavirus (HPV) vaccine has been licensed for use in women and men up to age 45 years in the United States. The cost-effectiveness of HPV vaccination for women and men aged 30 to 45 years in the context of cervical cancer screening practice was...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Public Library of Science (PLoS)
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/c7a9a728c2a34564b00d467c9944ca6f |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!